In what ways can extended acyclovir therapy lead to kidney issues?

How does acyclovir reach the kidneys?
Acyclovir is cleared almost entirely by the kidneys. When the drug arrives in the tubular lumen, it becomes less soluble and can crystallize if urine is acidic or dehydrated. Crystals lodge in the distal tubules, causing mechanical obstruction and inflammation.

What happens clinically when crystals form?
Patients develop a sudden rise in creatinine within days of high-dose therapy. Urine shows white blood cells and red blood cells without bacteria. Renal biopsy shows needle-shaped crystals inside the tubules and acute tubular necrosis.

What risk factors raise the likelihood of crystal nephropathy?
Older age, preexisting chronic kidney disease, high peak doses, rapid infusion rates, and concurrent use of other nephrotoxic drugs all increase probability. Dehydration from fever or vomiting is a common trigger.

What happens if therapy is continued after the first signs?
Continued dosing widens the clearance gap between drug arrival and urine flow. The already partially blocked tubules receive more drug, further widening the obstruction. Resulting azotemia slows drug clearance, raising systemic exposure and verschärft the process.

What other kidney patterns appear in long-term use?
Rare cases of interstitial nephritis with eosinophilia appear after weeks rather than days. Patients show low-grade proteinuria and mild elevation in creatinine. Biopsy shows lymphocytic infiltrate without crystals.

How long does eskalation usually take?
Crystal-related injury shows up in 2–7 days. Interstitial nephritis tends to appear after 2–4 weeks. Both patterns require immediate discontinuation and hydration.

When does patent expire?
Acyclovir itself is generic. Extended-release formulations and new salt forms are still patented by individual manufacturers. Patent dates vary by country and formulation.